PPARγ and Its Agonists in Chronic Kidney Disease
Y Ma, M Shi, Y Wang, J Liu - International Journal of …, 2020 - Wiley Online Library
Chronic kidney disease (CKD) has become a global healthcare issue. CKD can progress to
irreversible end‐stage renal diseases (ESRD) or renal failure. The major risk factors for CKD …
irreversible end‐stage renal diseases (ESRD) or renal failure. The major risk factors for CKD …
[HTML][HTML] Synthesis and antimicrobial evaluation of fatty chain substituted 2, 5-dimethyl pyrrole and 1, 3-benzoxazin-4-one derivatives
Fatty acids themselves have a number of biological properties and its easy intake by the
human body will focus to the synthesis of many heterocyclic moiety substituted with fatty acid …
human body will focus to the synthesis of many heterocyclic moiety substituted with fatty acid …
[HTML][HTML] Molecular docking of glyceroneogenesis pathway intermediates with peroxisome proliferator-activated receptor-alpha (PPAR-α)
Peroxisome proliferator-activated receptor alpha (PPAR-α) belongs to the nuclear receptor
superfamily of proteins. It is one of the principle regulators of metabolism and lipid …
superfamily of proteins. It is one of the principle regulators of metabolism and lipid …
[HTML][HTML] Docking of Glycokinase with Oxo, Sulfo, and Seleno Derivatives of the Carboxamide Activator S41
GM Ndefi, AS Lundemba, DD Bibelayi… - Crystal Structure Theory …, 2020 - scirp.org
Inactivation of Glucokinase (GK) is associated with diabetes. Therefore, design of drugs
targeting the GK activator site is currently integrated in the strategy of the diabetes treatment …
targeting the GK activator site is currently integrated in the strategy of the diabetes treatment …
[PDF][PDF] Exploring Novel ALK Inhibitors using Energy Based Pharmacophore Mapping and High-throughput Virtual Screening
Introduction: Recent years has witnessed major paradigm shifts in the treatment of NSCLC
with the emergence of biomarkers and targeted therapies. Most importantly, ALK is a …
with the emergence of biomarkers and targeted therapies. Most importantly, ALK is a …